Axon Enterprise (NASDAQ:AXON) Receives Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Axon Enterprise (NASDAQ:AXON) in a research note released on Tuesday, Benzinga reports. They currently have a $375.00 price target on the biotechnology company’s stock.

AXON has been the subject of a number of other reports. Barclays upped their price target on Axon Enterprise from $296.00 to $308.00 and gave the company an overweight rating in a report on Thursday, February 29th. Needham & Company LLC reissued a buy rating and issued a $400.00 price objective on shares of Axon Enterprise in a report on Tuesday. Argus initiated coverage on shares of Axon Enterprise in a research note on Wednesday, March 13th. They set a buy rating and a $380.00 target price for the company. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $330.00 to $365.00 and gave the stock an overweight rating in a research note on Thursday, April 11th. Finally, StockNews.com lowered shares of Axon Enterprise from a buy rating to a hold rating in a research report on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $327.00.

Axon Enterprise Trading Down 4.6 %

Shares of NASDAQ:AXON opened at $312.73 on Tuesday. The company has a market cap of $23.60 billion, a PE ratio of 135.97 and a beta of 0.91. The company’s 50 day moving average is $310.77 and its two-hundred day moving average is $267.13. Axon Enterprise has a 52 week low of $175.37 and a 52 week high of $329.87. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Monday, May 6th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. The firm had revenue of $460.74 million for the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. Axon Enterprise’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.51 earnings per share. Equities analysts predict that Axon Enterprise will post 2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Several institutional investors have recently modified their holdings of AXON. ICA Group Wealth Management LLC acquired a new position in Axon Enterprise during the fourth quarter worth $26,000. Trivant Custom Portfolio Group LLC acquired a new position in shares of Axon Enterprise during the 1st quarter worth $31,000. BKM Wealth Management LLC purchased a new stake in shares of Axon Enterprise in the 4th quarter worth about $32,000. First PREMIER Bank acquired a new stake in Axon Enterprise in the 1st quarter valued at about $33,000. Finally, Key Financial Inc increased its holdings in Axon Enterprise by 367.6% during the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.